By allergytalk
5
4646 ratings
The podcast currently has 69 episodes available.
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 3: Maintenance and Reliever Therapy in Moderate to Severe Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: Leonard B. Bacharier, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: MART therapy, ICS/formoterol, FDA guidelines, pediatric application.
Learning Objectives:
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron
This podcast miniseries is supported by a grant from AstraZeneca.
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 2: Implementing an Anti-inflammatory Reliever in Mild Asthma
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Leonard B. Bacharier, MD, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: anti-inflammatory reliever (AIR), pediatric vs. adult patients, GINA guidelines, insurance challenges.
Learning Objectives:
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Leonard B. Bacharier, MD, FACAAI
Advisor: DBV Technologies
Consultant: AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi
Researcher: AstraZeneca, Sanofi
Speaker: Regeneron, Sanofi
This podcast miniseries is supported by a grant from AstraZeneca.
The Asthma Urgency Shifting the Rescue Paradigm: A Call-to-Action Miniseries
Episode 1: The Limitations of Bronchodilator Only Rescue Therapy
Host: Gerald B. Lee, MD, FACAAI
Experts: William C. Anderson III, MD, FACAAI, Alan P. Baptist, MD, MPH, FACAAI
Asthma exacerbations continue to affect over 40% of asthma patients, which not only disrupts their quality of life but can lead to permanent loss of lung function. The goal of this podcast miniseries is to review why an anti-inflammatory reliever has become the standard of care in asthma management and to provide tips on how to implement this therapy into your practice! Topics include: pathophysiology, exacerbations, anti-inflammatory reliever (AIR), SMART therapy.
Learning Objectives:
Reference:
Lee JJ, Baptist AP, Blake KV. Lack of awareness and knowledge of NHLBI 2020 Asthma Focused Updates. J Allergy Clin Immunol Pract. 2024 Jan;12(1):226-228.e2. doi: 10.1016/j.jaip.2023.09.035. Epub 2023 Oct 5. PMID: 37802252.
Speaker Disclosures:
Gerald B. Lee, MD, FACAAI
No relevant financial relationships with ineligible companies to disclose
William C. Anderson III, MD, FACAAI
Advisor: Genentech, Regeneron, Sanofi
Alan P. Baptist, MD, MPH, FACAAI
Advisor: AstraZeneca, GlaxoSmithKline, Regeneron, Sanofi
Researcher: AstraZeneca, Novartis, Regeneron
This podcast miniseries is supported by a grant from AstraZeneca.
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Gut microbiota maturity mediates the protective effect of siblings on food allergy.
Duration of skin prick test refractory period following food-induced allergic reactions.
Clinical and immunological phenotypes of selective IgM deficiency in children: Results from a multicenter study.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
Welcome to Season Three of Allergytalk!
Today we joined by Dr. Shyam Joshi, MD, Associate Professor and Section Chief at Oregon Health & Science University and Associate Editor of Allergy Watch. We will be reviewing the January-February issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
To read archived issues of AllergyWatch, head over to http://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Outcomes of oral food challenges in a real-world setting, with predictors of outcomes.
Severe food allergy reactions are associated with α-tryptase.
Association of a Housing Mobility Program With Childhood Asthma Symptoms and Exacerbations.
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Fineman: Speaker: Takeda; Research: DBV, Novartis, and Alladapt
Dr. Joshi: Advisor: Genentech, Sanofi & Regeneron, Novartis, Takeda; Consultant, Executive Role: Nectar Allergy
Welcome to a Special Board Review Episode of AllergyTalk!
As the fall welcomes a new class of allergy/immunology fellows, the graduating fellows are studying for the fall ABAI board certification exam. I’m excited to be joined by the editorial team of the newly released 5th edition of the ACAAI Review of the Allergy & Immunology Boards, where we’ll talk about how you can prepare for the upcoming board exam!
Guests:
Joyce Yu, MD
Ben Prince, MD, MSCI
Resources for Board Review:
Exam Blueprint
ACAAI FIT and Board Review Resources (including the board review book)
AIM Self-Assessment: Volume One (2023)
AAAAI Allergy/Immunology Self Assessment
For information about CME credit, head over to http://education.acaai.org/allergytalk
Please rate our podcast on Apple Podcasts!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee has been a speaker for Novartis.
Dr. Prince is a Data Monitoring Committee Member for Eli Lilly
Dr. Yu has no relevant disclosures.
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Allergen Immunotherapy Enhances Airway Epithelial Antiviral Immunity in Patients with Allergic Asthma (VITAL Study): A Double-Blind Randomized Controlled Trial.
Omalizumab in Chronic Spontaneous Urticaria (CSU): Real-Life Experience in Dose/Interval Adjustments and Treatment Discontinuation.
Prevalence of CFTR variants in primary immunodeficiency patients with bronchiectasis is an important modifying cofactor.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Spriet have nothing to disclose
Dr. Fineman: Research: DBV, Novartis, Alladapt
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Sarah Spriet, DO, an allergist/immunologist at the Alexander T. Augusta Military Medical Center in Fort Belvoir, VA and an assistant editor of Allergy Watch. We will be reviewing the November-December 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit or to read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
The protective effect of moderate maternal peanut consumption on peanut sensitization and allergy.
Hymenoptera venom skin testing: Adopting an accelerated test protocol.
Treatment Failure and Adverse Events After Amoxicillin-Clavulanate vs Amoxicillin for Pediatric Acute Sinusitis.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Spriet have nothing to disclose
Dr. Fineman - Research: DBV, Novartis, Alladapt
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk . To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Racial and Ethnic Disparities in Allergen Immunotherapy Prescription for Allergic Rhinitis.
Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Chow have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
Welcome to Season Two of Allergytalk! In this season, we are going to introduce you to each of the Allergy Watch assistant editors who work so hard on scouring the literature in allergy and immunology and bring you the most interesting articles in every issue!
Today we joined by Dr. Tim Chow, an assistant professor at UT Southwestern and an assistant editor of Allergy Watch. We will be reviewing the July-August 2023 issue Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology.
You can also earn CME credit by listening to this podcast! For information about CME credit please visit https://education.acaai.org/allergytalk. To read archived issues of Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
Also, make sure you check out the ACAAI Community on DocMatter where we can continue the discussion about these articles!
Articles Reviewed:
Pharmacokinetic and pharmacodynamic comparison of epinephrine, administered intranasally and intramuscularly: An integrated analysis.
Wildfires and the Changing Landscape of Air Pollution-related Health Burden in California.
Differences in Hypersensitivity Reactions to Iodinated Contrast Media: Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.
Please rate our podcast on iTunes!
Please give us feedback, corrections, and suggestions!
Email feedback to: [email protected]
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Chow have nothing to disclose
Dr. Fineman Speaker: Takeda; Research: Aimmune, DBV, Biocryst
The podcast currently has 69 episodes available.
26,332 Listeners
456 Listeners
25,870 Listeners
12,460 Listeners
3,282 Listeners
111,405 Listeners
56,478 Listeners
1,029 Listeners
46 Listeners
84 Listeners
14,360 Listeners
304 Listeners
9,283 Listeners
2 Listeners